Clinical results of MetiMedi Pharmaceuticals’ Anti-EGFR targeted treatment for advanced colorectal cancer, METI-101, have demonstrated excellent safety with minimal adverse effects.

In addition, compared to the current standard therapy, cetuximab rechallenge, which shows a median overall survival (OS) of 8–9 months, METI-101 demonstrated superior efficacy with a median overall survival of 23.4 months, indicating an expected survival extension of more than 15 months.

For further details, please refer to the attached article from Yakup News.

View Full Article : https://www.yakup.com/news/index.html?mode=view&cat=12&nid=293558